In Silico joined the Unicorn Club on March 13, 2025 after raising a $110 million Series E funding round. Headquartered in Cambridge, Massachusetts, United States, In Silico provides an AI-enabled bioinformatics platform for drug discovery and biomarker development. Its solutions include custom drug discovery engines, biomarker discovery tools, aging research modules, and the PHARMA.AI product suite with PandaOmics, Chemistry42, and InClinico for accelerated drug development.
Keep reading to learn how In Silico scaled into a unicorn in genomics and life sciences tech.
What Is In Silico and What Does It Do?
Founded in 2014, In Silico is an AI-driven bioinformatics platform serving academia, pharmaceutical companies, and cosmetics industries. The platform provides solutions for custom drug discovery, biomarker identification, and aging research, enabling faster, data-driven development of therapeutics and diagnostics.
Its flagship product, PHARMA.AI, includes modules like PandaOmics, Chemistry42, and InClinico, allowing users to streamline drug discovery pipelines, predict compound efficacy, and analyze clinical trial potential using artificial intelligence.
How Much Funding Has In Silico Raised?
1. Series E Round
- Amount Raised: $110 million
- Date: January 7, 2025
- Lead Investors: eBridge Ventures, Deerfield
- Purpose: Expand AI bioinformatics platform, enhance PHARMA.AI modules, and scale enterprise adoption
2. Earlier Rounds (Seed to Series D)
- Cumulative Funding: ~$400 million
- Key Investors: eBridge Ventures, Deerfield, and other early-stage investors
- Purpose: Platform development, research expansion, and initial product launches
Total Funding Raised: $510 million
Latest Funding Date: January 7, 2025
Employee Count: 51–200 as of July 1, 2024
Key Investors
- eBridge Ventures
- Details: Venture capital firm investing in healthcare and life sciences startups
- Focus Areas: Genomics, AI-driven drug discovery, and biotechnology innovation
- Deerfield
- Details: Investment firm specializing in healthcare and life sciences
- Focus Areas: Therapeutics, diagnostics, and AI-enabled bioinformatics
Where Is In Silico’s Headquarters?
In Silico is headquartered in Cambridge, Massachusetts, United States, supporting research, AI platform development, and enterprise bioinformatics services.
What’s Next for In Silico?
In Silico plans to leverage its Series E funding to expand PHARMA.AI capabilities, accelerate AI-driven drug discovery pipelines, and grow partnerships with pharmaceutical, academic, and cosmetics companies. The company aims to enhance biomarker discovery, aging research tools, and predictive analytics for precision therapeutics.
Get Investor and Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Eve. Explore insights on legal AI, workflow automation, and high growth enterprise software startups shaping the future of legal technology.
Sign up for Free to access real time investor and funding intelligence.
